WHO
REGULATORY UPDATE
First Insulin Glargine biosimilar product prequalified
Published: 11/18/2026Detected: 10/6/2026
Summary preview
Adds the first insulin glargine biosimilar product (BT-DM007) to the WHO Prequalification Unit (PQT) list based on an abridged prequalification pathway leveraging an EMA marketing authorization.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountendocrinology
#WHO prequalification
#biosimilar
#insulin glargine
#abridged prequalification pathway
#EMA marketing authorization
Official Source Document Source Verified
Access the original document directly from WHO.